Xpert® MTB/RIF Ultra

Home / Tests / TB & Emerging Infectious Diseases

Enhanced performance in detecting drug-sensitive and -resistant Tuberculosis in less than 80 minutes

Test pack size(s)

50 Tests

GXMTB/RIF-ULTRA-50

Qty

Unit price

Subtotal

USD

$0.00

10 Tests

GXMTB/RIF-ULTRA-10

Qty

Unit price

Subtotal

USD

$0.00

Total

$0.00

The Need

Each day, close to 4,400 people lose their lives to TB and nearly 30,000 people fall ill with this preventable and curable disease¹
Globally, diagnosis of TB and drug-resistant TB remains a challenge, with a third of people with TB and two-thirds of people with drug-resistant TB not being detected¹
Precise and early detection of TB is needed to improve case management and significantly enhance the prevention of TB transmission²

1 World Health Organization Tuberculosis Report 2023 - https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023
2 Centers for Disease Control and Prevention—Guidelines for preventing the transmission of TB - https://www.cdc.gov/mmwr/preview/mmwrhtml/00001897.htm

The Solution

Xpert MTB/RIF Ultra provides fast and highly accurate detection of Mycobacterium Tuberculosis (MTB) and Rifampicin (RIF) resistance simultaneously from patient samples
Higher sensitivity, especially in smear-negative TB cases and among HIV-infected patients³
Simple three-step process with minimal hands-on time and results in ~80 min direct from sample
Designed to provide the most accurate MTB and Rifampicin detection utilizing multi-target and melt curves technology
Accurate detection of mixed infections

3 Aliasgar Esmail, et al, Comparison of Xpert MTB/RIF (G4) and Xpert Ultra, including trace readouts, for the diagnosis of pulmonary tuberculosis in a TB and HIV endemicsetting https://researchonline.lshtm.ac.uk/id/eprint/4661245/1/1-s2.0-S1201971220301442-main.pdf

The Impact

Early detection of MTB and resistance to Rifampicin enables faster access to the most appropriate treatment for better patient outcomes⁴
Increased access to front-line testing with Xpert MTB/RIF Ultra as part of active case finding and management can help limit community transmission⁵
Superior performance of Xpert MTB/RIF Ultra versus smear microscopy enables more people with MTB infections to be detected and treated earlier⁴

4 Charkravorty S, et al. The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing - https://journals.asm.org/doi/10.1128/mbio.00812-17
5 Belén Saavedra, et al. Performance of Xpert MTB/RIF Ultra for tuberculosis diagnosis in the context of passive and active case finding - https://erj.ersjournals.com/content/58/6/2100257